1. Scrip
  2. >>R&D

Pfizer’s Growing Hematology Pipeline Matures With New Hemophilia, Sickle Cell Data

Multiple Modalities Advance Across Non-Malignant Diseases

 
• By Mandy Jackson

The big pharma is building on its hematology legacy beyond coagulation factors with marstacimab and gene therapies for hemophilia, plus oral and injectable medicines for sickle cell disease.

3D rendering of red blood cells
• Source: Shutterstock

Pfizer Inc. has a long history in non-malignant hematology after bringing forward multiple coagulation factor replacement therapies for hemophilia, but the company has a renewed and growing presence in the space after investing in gene therapies for hemophilia, buying sickle cell drug developer Global Blood Therapeutics, Inc. and advancing additional treatments for both diseases.

The company presented results at the American Society of Hematology (ASH) meeting on 9 December from the Phase III BASIS clinical trial of its anti-tissue factor pathway inhibitor (TFPI) inhibitor marstacimab in hemophilia A and B as well as Phase II results from a Phase II/III trial of its sickle hemoglobin (HbS) polymerization inhibitor GBT021601 (GBT601)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.